摘要

Hyporesponsiveness (anti-HBs 10-100 IU/I) or non-responsiveness (anti-HBs < 10 IU/I) to hepatitis B vaccines is a problem in approximately 20-70% of HIV-positive patients. Mechanisms for impaired humoral and cellular immunity related to the HIV infection are reviewed.
Contributing risk factors like age, gender, CD4(+) T-cell count, HIV RNA load and coinfection with hepatitis C are highlighted. New developments in improving the HBV vaccine immunogenicity are discussed and clinical recommendations are given for HBV-re-vaccination of HIV patients who failed on standard HBV vaccination. (AIDS Rev. 2009;11:157-64)

  • 出版日期2009-9